The FDA has approved Bristol Myers Squibb and 2seventy Bio’s CAR-T therapy, Abecma, for earlier use in treating multiple myeloma, a type of blood cancer. This approval permits the use of Abecma in adults who have already received at least two prior treatments for relapsed or refractory forms of the disease. The FDA’s decision, which […]